Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
Company Details
- Employees
- 9
- Address
- 1155 Boulevard René-Lévesque O, #4100,canada
- in****@****ago.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- inversago.com
- Keywords
- CB1 Receptor, Metabolic Disorders, Diabetes, NASH, Pulmonary Fibrosis, Obesity, Diabetic Kidney Disease, Diabetic Nephropathy.
- HQ
- Montreal, Quebec
Inversago Pharma Questions
Inversago Pharma's website is inversago.com
Inversago Pharma's LinkedIn profile is https://ca.linkedin.com/company/inversago-pharma
Inversago Pharma has
9 employees.
View email and phone details for 9
employees at Inversago Pharma.
Inversago Pharma's industry is
Biotechnology Research
Inversago Pharma's top competitors are
Repare Therapeutics,
Ability Biotherapeutics,
Paraza Pharma Inc.,
Laurent Pharmaceuticals,
Modulari-T Bio,
Congruence Therapeutics,
Corealis Pharma Inc.,
Giiant Pharma Inc.,
Nomic Bio,
Cura Therapeutics Inc..
Inversago Pharma's support email address is info@inversago.com
Inversago Pharma's categories are Biotechnology Research
